| Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties TT Wager, X Hou, PR Verhoest, A Villalobos ACS chemical neuroscience 1 (6), 435-449, 2010 | 933 | 2010 |
| Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes TT Wager, RY Chandrasekaran, X Hou, MD Troutman, PR Verhoest, ... ACS chemical neuroscience 1 (6), 420-434, 2010 | 473 | 2010 |
| Central nervous system multiparameter optimization desirability: application in drug discovery TT Wager, X Hou, PR Verhoest, A Villalobos ACS chemical neuroscience 7 (6), 767-775, 2016 | 414 | 2016 |
| Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl … PR Verhoest, DS Chapin, M Corman, K Fonseca, JF Harms, X Hou, ... Journal of medicinal chemistry 52 (16), 5188-5196, 2009 | 240 | 2009 |
| Classification of strange attractors by integers GB Mindlin, XJ Hou, HG Solari, R Gilmore, NB Tufillaro Physical Review Letters 64 (20), 2350, 1990 | 226 | 1990 |
| Topological analysis of chaotic time series data from the Belousov-Zhabotinskii reaction GB Mindlin, HG Solari, MA Natiello, R Gilmore, XJ Hou Journal of Nonlinear Science 1, 147-173, 1991 | 210 | 1991 |
| Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development … L Zhang, A Villalobos, EM Beck, T Bocan, TA Chappie, L Chen, ... Journal of medicinal chemistry 56 (11), 4568-4579, 2013 | 178 | 2013 |
| Current and future roles of artificial intelligence in medicinal chemistry synthesis TJ Struble, JC Alvarez, SP Brown, M Chytil, J Cisar, RL DesJarlais, ... Journal of medicinal chemistry 63 (16), 8667-8682, 2020 | 163 | 2020 |
| Current landscape of phosphodiesterase 10A (PDE10A) inhibition TA Chappie, CJ Helal, X Hou Journal of medicinal chemistry 55 (17), 7299-7331, 2012 | 107 | 2012 |
| Structure-based design of novel human Pin1 inhibitors (I) C Guo, X Hou, L Dong, E Dagostino, S Greasley, RA Ferre, J Marakovits, ... Bioorganic & medicinal chemistry letters 19 (19), 5613-5616, 2009 | 106 | 2009 |
| Structure-based design of novel human Pin1 inhibitors (II) L Dong, J Marakovits, X Hou, C Guo, S Greasley, E Dagostino, RA Ferre, ... Bioorganic & Medicinal Chemistry Letters 20 (7), 2210-2214, 2010 | 104 | 2010 |
| Molecular transformer unifies reaction prediction and retrosynthesis across pharma chemical space Q Yang, V Sresht, P Bolgar, X Hou, JL Klug-McLeod, CR Butler Chemical communications 55 (81), 12152-12155, 2019 | 100 | 2019 |
| An efficient algorithm for fast O (N∗ ln (N)) box counting XJ Hou, R Gilmore, GB Mindlin, HG Solari Physics Letters A 151 (1-2), 43-46, 1990 | 88 | 1990 |
| Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: Structure–activity studies of bicyclic 2-pyridone … PS Dragovich, TJ Prins, R Zhou, TO Johnson, EL Brown, FC Maldonado, ... Bioorganic & medicinal chemistry letters 12 (5), 733-738, 2002 | 87 | 2002 |
| Design and Discovery of 6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one … PR Verhoest, KR Fonseca, X Hou, C Proulx-LaFrance, M Corman, ... Journal of medicinal chemistry 55 (21), 9045-9054, 2012 | 83 | 2012 |
| Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors AM Zuhl, CE Nolan, MA Brodney, S Niessen, K Atchison, C Houle, ... Nature communications 7 (1), 13042, 2016 | 71 | 2016 |
| Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug–drug interactions with a novel series of centrally efficacious BACE1 inhibitors MA Brodney, EM Beck, CR Butler, G Barreiro, EF Johnson, D Riddell, ... Journal of medicinal chemistry 58 (7), 3223-3252, 2015 | 71 | 2015 |
| Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy PR Verhoest, C Proulx-Lafrance, M Corman, L Chenard, CJ Helal, X Hou, ... Journal of medicinal chemistry 52 (24), 7946-7949, 2009 | 68 | 2009 |
| Quantitative assessment of the impact of fluorine substitution on P-glycoprotein (P-gp) mediated efflux, permeability, lipophilicity, and metabolic stability M Pettersson, X Hou, M Kuhn, TT Wager, GW Kauffman, PR Verhoest Journal of medicinal chemistry 59 (11), 5284-5296, 2016 | 63 | 2016 |
| Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors MM Claffey, CJ Helal, PR Verhoest, Z Kang, KS Fors, S Jung, J Zhong, ... Journal of medicinal chemistry 55 (21), 9055-9068, 2012 | 58 | 2012 |
